LONDON (ShareCast) - (ShareCast News) - ImmuPharma has reached a number of important milestones in the phase three clinical trial of Lupuzor.
The AIM listed company provided an update to the market on Wednesday about the drug trial, its lead programme for the potential breakthrough compound for life threatening auto immune disease Lupus.

In the US, the trial has been approved by a major central institutional review board as the first trial locations will be set up in late November and early December, and recruiting patients after that.

In Europe, the study has been submitted to the centralised Voluntary Harmonisation Procedure ion late October, for which there is a 60 day review window.

ImmuPharma said it will run the trial in 45 sites - 10 in the US and 35 in Europe - with 270 potential patients to be screened.

Newly-appointed chairman Tim McCarthy said he's had time to review the progress of the trial.

"I am confident that given the dedication and expertise of the ImmuPharma team combined with the experience of [research organisation] Simbec-Orion, the study will progress as planned with the anticipation of completing the study by the end of 2017."

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE